Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
486 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape. Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2017 18Number of Products under Development by Companies, H1 2017 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2017 18Number of Products under Development by Companies, H1 2017 The guide covers therapeutics under Development by Companies /Universities /Institutes, Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2017 18Number of Products under Development by Companies, H1 2017 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2017 18Number of Products under Development by Companies, H1 2017 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology). - The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents
2 Introduction 6 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview 7 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Development 8 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 25 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development 39 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles 71 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 452 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 456 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 458 Appendix 474
List of Tables
Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), H1 2017 19 Number of Products under Development by Companies, H1 2017 21 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 22 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 23 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 24 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 25 Number of Products under Development by Universities/Institutes, H1 2017 26 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 28 Products under Development by Companies, H1 2017 29 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 30 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 31 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 32 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 33 Products under Development by Universities/Institutes, H1 2017 34 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 35 Number of Products by Stage and Target, H1 2017 37 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 38 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 39 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 40 Number of Products by Stage and Mechanism of Action, H1 2017 42 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 43 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 44 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 45 Number of Products by Stage and Route of Administration, H1 2017 47 Number of Products by Stage and Molecule Type, H1 2017 49 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc, H1 2017 50 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Altor BioScience Corp, H1 2017 50 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by arGEN-X BV, H1 2017 51 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017 52 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Array BioPharma Inc, H1 2017 53 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H1 2017 53 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Atara Biotherapeutics Inc, H1 2017 54 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings Inc, H1 2017 54 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx Ltd, H1 2017 55 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioSight Ltd, H1 2017 55 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BLR Bio LLC, H1 2017 56 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical Inc, H1 2017 56 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2017 57 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia AB, H1 2017 57 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corp, H1 2017 58 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cellectar Biosciences Inc, H1 2017 58 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cellectis SA, H1 2017 59 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cielo Therapeutics Inc, H1 2017 59 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Constellation Pharmaceuticals Inc, H1 2017 60 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 60 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017 61 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eisai Co Ltd, H1 2017 61 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by EpiZyme Inc, H1 2017 62 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Galena Biopharma Inc, H1 2017 62 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd, H1 2017 63 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlaxoSmithKline Plc, H1 2017 63 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlycoMimetics Inc, H1 2017 64 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hovione FarmaCiencia SA, H1 2017 64 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hybrigenics SA, H1 2017 65 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2017 65 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Immune Pharmaceuticals Inc, H1 2017 66 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corp, H1 2017 66 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017 67 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Johnson & Johnson, H1 2017 67 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Juno Therapeutics Inc, H1 2017 68 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corp, H1 2017 68 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H1 2017 69 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017 69 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Mesoblast Ltd, H1 2017 70 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 70 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Ltd, H1 2017 71 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H1 2017 71 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by OncoImmune Inc, H1 2017 72 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by OncoTherapy Science Inc, H1 2017 72 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 73 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Oribase Pharma, H1 2017 73 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc, H1 2017 74 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pharma Mar SA, H1 2017 74 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by PharmaEssentia Corp, H1 2017 75 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Phylogica Ltd, H1 2017 75 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Selvita SA, H1 2017 76 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Shenogen Pharma Group Ltd, H1 2017 76 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by SignalChem Lifesciences Corp, H1 2017 77 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Stemline Therapeutics Inc, H1 2017 77 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 78 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Synactix Pharmaceuticals Inc, H1 2017 78 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Syndax Pharmaceuticals Inc, H1 2017 79 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 79 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017 80 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Tragara Pharmaceuticals Inc, H1 2017 80 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by VioQuest Pharmaceuticals Inc, H1 2017 81 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Xencor Inc, H1 2017 81 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 463 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 (Contd..1), H1 2017 464 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 (Contd..2), H1 2017 465 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 (Contd..3), H1 2017 466 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H1 2017 467 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H1 2017 (Contd..1), H1 2017 468
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
